Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain

Hernando Knobel(Hospital General de Granollers), Elena Refollo(Hospital Universitario La Paz), Xavier Fulladosa(Bellvitge University Hospital), Rosario Palacios(Bellvitge University Hospital), José Ramón Blanco, Antonio Antela(Complejo Hospitalario Universitario de Santiago), Peré Domingo(Hospital de Sant Pau), Vicente Estrada(Instituto de Salud Carlos III), Ignacio Suárez-Lozano(Universidad de Huelva), Félix Gutiérrez(Universitat de Miguel Hernández d'Elx)
Enfermedades infecciosas y microbiologia clinica (English ed )
May 28, 2019
10.1016/j.eimce.2018.09.005
Cited by 6

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
|PLoS Medicine|2013|362
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
|The Lancet|2006|343